ClinicalTrials.gov
public full text
Public Domain
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)#1363355
- Activation of Apoptosis-related Receptors on Alveolar Macrophages#1008778
- A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)#1095703
- Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)#806940
- Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole#886908
Record · ID 1371264
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive